



RESPONSE UNDER 37 C.F.R. § 1.116
EXPEDITED PROCEDURE REQUESTED
EXAMINING GROUP 1600
PATENT

Attorney Docket No. 05273.0095-00000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
Atsushi OZAKI et al.) Group Art Unit: 1614
)
Application No.: 10/523,020) Examiner: R. J. Henley, III
)
Filed: February 2, 2005) Confirmation No.: 7467
)
For: METHOD FOR TREATING) **Mail Stop AF**
SEVERE HEART FAILURE AND)
MEDICAMENT THEREFOR)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

AMENDMENT AFTER FINAL

In reply to the Final Office Action mailed August 2, 2007, the period for response having been extended to December 2, 2007, by a request for extension of 1 month and fee payment filed concurrently herewith, and pursuant to 37 C.F.R. § 1.116, Applicant proposes that this application be amended as follows:

Amendments to the Claims are reflected in the listing of claims on page 2 of this paper.

Remarks/Arguments follow the amendment sections of this paper.

Attachments to this amendment are:

12/03/2007 JADD01 00000029 10523020

A) The Heart Failure Society of America Guidelines,

01 FC:1251

120.00 OP

Journal of Cardiac Failure 1999, Vol. 5: 357-82;

- B) Remme and Swedberg, Guidelines for the diagnosis and treatment of chronic heart failure, European Heart Journal 2001; 22: 1567-60;**
- C) Cooper H. A., Circulation, Journal of the American Heart Association 1999, 100; 1311-1315;**
- D) JAMA, March 28, 2007, Vol. 297, No. 12, 1319-1331.**